HK1187540A1 - 用於治療癌症的 甲基氨基苯氧基 吡啶- -基-苯甲酰胺衍生物 - Google Patents
用於治療癌症的 甲基氨基苯氧基 吡啶- -基-苯甲酰胺衍生物Info
- Publication number
- HK1187540A1 HK1187540A1 HK14100670.1A HK14100670A HK1187540A1 HK 1187540 A1 HK1187540 A1 HK 1187540A1 HK 14100670 A HK14100670 A HK 14100670A HK 1187540 A1 HK1187540 A1 HK 1187540A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methylaminophenoxy
- pyrdin
- treating cancer
- benzamide derivatives
- benzamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38939310P | 2010-10-04 | 2010-10-04 | |
PCT/JP2011/073165 WO2012046825A1 (en) | 2010-10-04 | 2011-10-03 | 4- (methylaminophenoxy) pyrdin- 3 - yl - benzamide derivatives for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1187540A1 true HK1187540A1 (zh) | 2014-04-11 |
Family
ID=44872549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14100670.1A HK1187540A1 (zh) | 2010-10-04 | 2014-01-22 | 用於治療癌症的 甲基氨基苯氧基 吡啶- -基-苯甲酰胺衍生物 |
Country Status (29)
Country | Link |
---|---|
US (7) | US8946437B2 (zh) |
EP (1) | EP2624833B1 (zh) |
JP (1) | JP5715690B2 (zh) |
KR (1) | KR101797797B1 (zh) |
CN (1) | CN103189061B (zh) |
AR (1) | AR083287A1 (zh) |
AU (1) | AU2011313236B2 (zh) |
BR (1) | BR112013007841B1 (zh) |
CA (1) | CA2813153C (zh) |
CO (1) | CO6660459A2 (zh) |
DK (1) | DK2624833T3 (zh) |
EA (1) | EA021627B1 (zh) |
ES (1) | ES2526574T3 (zh) |
HK (1) | HK1187540A1 (zh) |
HR (1) | HRP20141237T1 (zh) |
IL (1) | IL225520A (zh) |
MX (1) | MX2013003589A (zh) |
MY (1) | MY157563A (zh) |
NZ (1) | NZ609151A (zh) |
PL (1) | PL2624833T3 (zh) |
PT (1) | PT2624833E (zh) |
RS (1) | RS53749B1 (zh) |
SG (1) | SG189146A1 (zh) |
SI (1) | SI2624833T1 (zh) |
SM (1) | SMT201500056B (zh) |
TW (1) | TWI526431B (zh) |
UA (1) | UA110037C2 (zh) |
WO (1) | WO2012046825A1 (zh) |
ZA (1) | ZA201302332B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2624833T3 (pl) * | 2010-10-04 | 2015-05-29 | Otsuka Pharma Co Ltd | Pochodne 4-(metyloaminofenoksy)pirydyn-3-ylo-benzamidu do leczenia nowotworów |
JP6066806B2 (ja) * | 2012-04-03 | 2017-01-25 | 大塚製薬株式会社 | 医薬 |
MX2021011704A (es) * | 2019-03-25 | 2021-10-22 | Otsuka Pharma Co Ltd | Composicion antitumoral. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
JP2001089412A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
EP1773797A2 (en) | 2004-08-06 | 2007-04-18 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds |
MY146514A (en) | 2005-12-05 | 2012-08-15 | Otsuka Pharma Co Ltd | Diarylether derivatives as antitumor agents |
UA95978C2 (ru) * | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
PL2624833T3 (pl) * | 2010-10-04 | 2015-05-29 | Otsuka Pharma Co Ltd | Pochodne 4-(metyloaminofenoksy)pirydyn-3-ylo-benzamidu do leczenia nowotworów |
MX2021011704A (es) * | 2019-03-25 | 2021-10-22 | Otsuka Pharma Co Ltd | Composicion antitumoral. |
-
2011
- 2011-10-03 PL PL11773326T patent/PL2624833T3/pl unknown
- 2011-10-03 DK DK11773326T patent/DK2624833T3/en active
- 2011-10-03 AU AU2011313236A patent/AU2011313236B2/en active Active
- 2011-10-03 NZ NZ60915111A patent/NZ609151A/en unknown
- 2011-10-03 UA UAA201303865A patent/UA110037C2/uk unknown
- 2011-10-03 AR ARP110103657 patent/AR083287A1/es unknown
- 2011-10-03 MY MYPI2013001147A patent/MY157563A/en unknown
- 2011-10-03 KR KR1020137008052A patent/KR101797797B1/ko active IP Right Grant
- 2011-10-03 WO PCT/JP2011/073165 patent/WO2012046825A1/en active Application Filing
- 2011-10-03 EP EP20110773326 patent/EP2624833B1/en active Active
- 2011-10-03 MX MX2013003589A patent/MX2013003589A/es active IP Right Grant
- 2011-10-03 RS RS20150024A patent/RS53749B1/en unknown
- 2011-10-03 SG SG2013023148A patent/SG189146A1/en unknown
- 2011-10-03 CN CN201180047707.2A patent/CN103189061B/zh active Active
- 2011-10-03 PT PT11773326T patent/PT2624833E/pt unknown
- 2011-10-03 TW TW100135750A patent/TWI526431B/zh active
- 2011-10-03 BR BR112013007841-3A patent/BR112013007841B1/pt active IP Right Grant
- 2011-10-03 SI SI201130409T patent/SI2624833T1/sl unknown
- 2011-10-03 ES ES11773326.1T patent/ES2526574T3/es active Active
- 2011-10-03 EA EA201390323A patent/EA021627B1/ru unknown
- 2011-10-03 US US13/877,276 patent/US8946437B2/en active Active
- 2011-10-03 JP JP2013515439A patent/JP5715690B2/ja active Active
- 2011-10-03 CA CA2813153A patent/CA2813153C/en active Active
-
2013
- 2013-03-28 ZA ZA2013/02332A patent/ZA201302332B/en unknown
- 2013-04-02 IL IL225520A patent/IL225520A/en active IP Right Grant
- 2013-04-16 CO CO13097703A patent/CO6660459A2/es unknown
-
2014
- 2014-01-22 HK HK14100670.1A patent/HK1187540A1/zh unknown
- 2014-12-17 US US14/574,102 patent/US20150105432A1/en not_active Abandoned
- 2014-12-18 HR HRP20141237AT patent/HRP20141237T1/hr unknown
-
2015
- 2015-03-09 SM SM201500056T patent/SMT201500056B/xx unknown
-
2016
- 2016-11-28 US US15/362,561 patent/US20170298023A1/en not_active Abandoned
-
2018
- 2018-05-02 US US15/969,690 patent/US20180265471A1/en not_active Abandoned
-
2019
- 2019-06-13 US US16/440,924 patent/US20200031773A1/en not_active Abandoned
-
2020
- 2020-09-30 US US17/039,731 patent/US20210017134A1/en not_active Abandoned
-
2022
- 2022-12-30 US US18/148,672 patent/US20230139808A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1252832A1 (zh) | 用於治療結腸直腸癌的方法 | |
HK1200363A1 (zh) | 用於治療癌症的化合物 | |
EP2542081A4 (en) | COMPOSITIONS FOR CANCER TREATMENT | |
EP2542584B8 (en) | Methods for treating pancreatic cancer | |
SI3412687T1 (sl) | Postopek zdravljenja DLBCL | |
EP2635286A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
ZA201203449B (en) | Sulfoxide derivatives for treating tumors | |
IL225623A0 (en) | Psoriasis treatment methods | |
IL222958A0 (en) | Cancer treatment | |
HRP20160851T1 (hr) | Prediktori za liječenje karcinoma | |
IL228644A0 (en) | Cancer treatment methods | |
EP2608671A4 (en) | COMPOUNDS USED IN THE TREATMENT OF CANCER | |
HK1247207A1 (zh) | 可治療癌症和其他疾病的新化合物 | |
ZA201503005B (en) | Ingenol-derived compounds useful for treating cancer | |
HK1187540A1 (zh) | 用於治療癌症的 甲基氨基苯氧基 吡啶- -基-苯甲酰胺衍生物 | |
EP2563353A4 (en) | COMPOUNDS FOR ANTIFUNGAL TREATMENT | |
GB201019034D0 (en) | Treatment for tumors | |
GB0914322D0 (en) | Compounds for treating cancer | |
AU2012901918A0 (en) | Methods for treating cancer | |
GB201301168D0 (en) | Cancer treatment |